Table IV.
Day of life | Days after CTT | Causes of Death (N = 28)* |
---|---|---|
| ||
Related to Infection (n = 13) | ||
| ||
471 | 24 | Progression of underlying PIV3 pneumonia |
398 | 44 | Sepsis |
586 | 89 | Death secondary to disseminated Candida infection |
247 | 103 | Progressive cerebral atrophy due to CMV |
181 | 130 | Sepsis |
199 | 130 | Sepsis |
350 | 149 | Respiratory failure from disseminated mycobacterial infection |
264 | 160 | Respiratory failure due to respiratory syncytial virus |
416 | 234 | Respiratory failure secondary to sepsis from Candida tropicalis and C parapsilosis |
382 | 252 | Respiratory complications from CMV infection |
804 | 263 | Multiorgan system failure as seen in severe septic shock |
856 | 339 | Methicillin resistant Staphylococcus aureus bacteremia |
824 | 375 | Presumed sepsis |
| ||
All Except for Infection (n = 15) | ||
| ||
107 | 0 | Hemorrhage with Nissen fundoplication surgery |
172 | 45 | Respiratory failure |
162 | 66 | Severe bilateral intraventricular hemorrhage |
268 | 82 | Hypoxia |
537 | 108 | Cardiorespiratory arrest related to anasarca |
5879 | 116 | Progression of EBV lymphoma resulting in intracranial bleeding and death |
510 | 128 | Large right parietal hemorrhage |
256 | 137 | Respiratory failure |
667 | 229 | Respiratory failure |
392 | 289 | Respiratory failure |
982 | 480 | Sudden catastrophic intracranial hemorrhage |
1622 | 950 | Not reported |
1713 | 1617 | Cardiopulmonary arrest |
2918 | 2769 | Respiratory failure |
3311 | 3116 | Respiratory failure |
CMV, cytomegalovirus; EBV, Epstein-Barr virus; PIV3, parainfluenza virus type 3
Includes 2 deaths in patients who withdrew from the study prior to having a reportable adverse event.